Life expectancy in patients with pituitary adenoma receiving growth hormone replacement

Olsson, Daniel S; Trimpou, Penelope; Hallén, Tobias; Bryngelsson, Ing‐Liss; Andersson, Eva; Skoglund, Thomas; Bengtsson, Bengt‐Åke; Johannsson, Gudmundur; Nilsson, Anders

doi:10.1530/eje-16-0450

Cited by 42 publications

(32 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lately, partly due to a recently published study, a growing body of evidence is showing that GH replacement therapy is associated with reduced excess mortality or normalized mortality compared to the general population [5,16]. We have shown that GH replacement therapy is associated with normalized mortality among over 400 non-functioning pituitary adenoma patients receiving or not receiving GH replacement, who were followed for 10 years [5].…”

mentioning

confidence: 87%

“…The standardized mortality ratio (SMR) of hypopituitary patients (1.8-1.9) can be compared to that of morbidly obese patients (1.6), showing the very real effect of hormonal deficiencies on life expectancy [1,2,4]. We believe that the source of the excess mortality originates from non-physiological replacement therapy, untreated deficiencies, local effects of the tumor itself, and adverse effects of tumor treatment (mostly radiotherapy) [2,[5][6][7].…”

mentioning

confidence: 99%

“…Long-term studies on the effect of GH replacement therapy have since shown an improvement in many of these features, such as improved lean body mass, decreased body fat, beneficial effects on plasma lipids, positive effects on intima media thickness, improvement in bone mineral density, and better quality of life [15]. Lately, partly due to a recently published study, a growing body of evidence is showing that GH replacement therapy is associated with reduced excess mortality or normalized mortality compared to the general population [5,16]. We have shown that GH replacement therapy is associated with normalized mortality among over 400 non-functioning pituitary adenoma patients receiving or not receiving GH replacement, who were followed for 10 years [5].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Hypopituitarism—needs modern individualized treatment

Olsson

Bengtsson

2016

Endocrine

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 87%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Hypopituitarism—needs modern individualized treatment

Olsson

Bengtsson

2016

Endocrine

Self Cite

View full text Add to dashboard Cite

“…After final screening, data from 10 selected studies published from 2002 to 2017 were extracted for inclusion in the current analysis [12]- [21].…”

Section: Study Identificationmentioning

confidence: 99%

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

Zeng¹,

Song²,

Lin³

et al. 2017

OJEMD

View full text Add to dashboard Cite

The growth hormone (GH) replacement therapy in adult growth hormone deficiency (AGHD) is now well developed, nevertheless, the safety of GH replacement, especially the incidence of cancer in these patients remains to be further clarified. To summarize the evidence on the safety of using GH in AGHD, we conduct this meta-analysis to assess the relationship between the risk of cancer and GH replacement therapy. Randomized controlled trials and cohort studies involved in GH therapy for AGHD were selected. Meta-analysis was performed and risk ratio (RR) was pooled with 95% confidence interval (CI) to investigate the relationship between GH replacement and the risk of cancer. The result indicated that there was no evidence to draw a conclusion that GH replacement therapy will increase the risk of cancer (P = 0.001, RR = 0.77, 95% CI [0.65, 0.90]). Meanwhile, according to the calculated analysis, the replacement therapy might even reduce the risk of cancer. Furthermore, subgroup analysis demonstrated that there was no correlation between replacement therapy of GH and the risk of cancer both in prospective and retrospective cohort design research, and in prospective group, the risk of cancer even decreased (P = 0.0002, RR = 0.71, 95%CI [0.59, 0.85]). In conclusion, our study corroborates evidence from previous studies showing that GH replacement therapy in AGHD patients would not increase the risk of cancer; instead, it might be even decrease cancer risk. The results suggested that GH replacement therapy in AGHD patients was safe.#These authors contributed equally to this work.

show abstract

“…Highest mortality is among younger patients, women and patients with diabetes insipidus (4). A recent study from Sweden shows a decline in mortality in patiens optimally replaced including GH replacement therapy (5).…”

Section: Introductionmentioning

confidence: 99%

DIAGNOSIS OF ENDOCRINE DISEASE: Expanding the cause of hypopituitarism

Pekić

Popović

2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Hypopituitarism is defined as one or more pituitary hormone deficits due to a lesion in the hypothalamic-pituitary region. By far, the most common cause of hypopituitarism associated with a sellar mass is a pituitary adenoma. A high index of suspicion is required for diagnosing hypopituitarism in several other conditions such as other massess in the sellar and parasellar region, brain damage caused by radiation and by traumatic brain injury, vascular lesions, infiltrative/immunological/inflammatory diseases (lymphocytic hypophysitis, sarcoidosis and hemochromatosis), infectious diseases and genetic disorders. Hypopituitarism may be permanent and progressive with sequential pattern of hormone deficiencies (radiation-induced hypopituitarism) or transient after traumatic brain injury with possible recovery occurring years from the initial event. In recent years, there is increased reporting of less common and less reported causes of hypopituitarism with its delayed diagnosis. The aim of this review is to summarize the published data and to allow earlier identification of populations at risk of hypopituitarism as optimal hormonal replacement may significantly improve their quality of life and life expectancy.Correspondence should be addressed to V Popovic

show abstract

Life expectancy in patients with pituitary adenoma receiving growth hormone replacement

Cited by 42 publications

References 32 publications

Hypopituitarism—needs modern individualized treatment

Hypopituitarism—needs modern individualized treatment

Growth Hormone Replacement Therapy in Adult Growth Hormone Deficiency and Risk of Cancer: A Meta-Analysis

DIAGNOSIS OF ENDOCRINE DISEASE: Expanding the cause of hypopituitarism

Contact Info

Product

Resources

About